Open Access

EDITORIAL

Leonard G. Gomella
Canadian Journal of Urology, Vol.30, No.3, pp. 11520-11521, 2023
Abstract This article has no abstract. More >

View

31

Download

45

Open Access

LEGENDS IN UROLOGY

Gopal Badlani
Canadian Journal of Urology, Vol.30, No.3, pp. 11522-11524, 2023
Abstract This article has no abstract. More >

View

36

Download

44

Open Access

BOOK REVIEW

Alan W. Partin, Louis R. Kavoussi, Craig A. Peters, Roger R. Dmochowski
Canadian Journal of Urology, Vol.30, No.3, pp. 11525-11525, 2023
Abstract This article has no abstract. More >

View

31

Download

39

Open Access

ARTICLE

J. Ryan Mark¹, Leonard G. Gomella¹, Costas D. Lallas¹, Katherine E. Smentkowski¹, Anne Calvaresi¹, Nathan Handley², Robert B. Den³, Patrick Mille², William J. Tester², Jean Hoffman-Censits⁴, Adam P. Dicker³, Edward Klonicke¹, Ethan Halpern⁵, Peter McCue⁵, W. Kevin Kelly², Edouard J. Trabulsi⁶
Canadian Journal of Urology, Vol.30, No.3, pp. 11526-11531, 2023
Abstract Introduction: We report the impact of our 25-year multidisciplinary care delivery model experience on patients with muscle invasive bladder cancer treated at our National Cancer Institute (NCI)-designated Sidney Kimmel Cancer Center at Jefferson University. To our knowledge, our multidisciplinary genitourinary cancer clinic (MDC) is the longest continuously operating center of its kind at an NCI Cancer Center in the United States.
Materials and methods: We selected a recent group of patients with cT2-4 N0-1 M0 bladder cancer seen in the Sidney Kimmel Cancer Center Genitourinary Oncology MDC from January 2016 to September 2019. These patients were identified… More >

View

35

Download

47

Open Access

ARTICLE

Fadl Hamouche, Rei Unno, Nizar Hakam, Leslie Bernal Charondo, Heiko Yang, Justin Ahn, David B. Bayne, Marshall L. Stoller, Thomas Chi
Canadian Journal of Urology, Vol.30, No.3, pp. 11532-11537, 2023
Abstract Introduction: To evaluate the clinical characteristics as well as the postoperative course of urolithiasis patients undergoing a ureteroscopy (URS) without stent placement.
Materials and methods: This was a prospective case cohort study utilizing data collected in the Registry for Stones of the Kidney and Ureter (ReSKU) from a single institution between October 2015 and December 2020. We identified all consecutive patients undergoing URS for stone disease and analyzed data encompassing demographics, medical history, intra and postoperative characteristics, including complications and postoperative symptoms. Univariate and multivariate logistic regression analyses were performed based on the presence or absence of… More >

View

32

Download

40

Open Access

ARTICLE

John V. Dudinec^1,*, Sabrina M. Wang^1,*, Srinath Kotamarti¹, Kostantinos E. Morris², Thomas J. Polascik¹, Judd W. Moul¹
Canadian Journal of Urology, Vol.30, No.3, pp. 11538-11544, 2023
Abstract Introduction: The clinical utility of concurrent Prostate Health Index (PHI) and ExosomeDx Prostate Intelliscore (EPI) testing is unclear. We sought to examine the performance of combined PHI and EPI testing on men undergoing elevated PSA work up.
Materials and methods: Patients who received both EPI and PHI testing were identified from an institutional database of men referred to urology for an elevated total PSA. Cut points of EPI > 15.6 and PHI ≥ 36 were used to denote a positive test. Patients were placed into one of four groups determined by combination of EPI and PHI results.… More >

View

33

Download

42

Open Access

COMMENTARY

Jonathan E. Heinlen
Canadian Journal of Urology, Vol.30, No.3, pp. 11545-11545, 2023
Abstract This article has no abstract. More >

View

36

Download

42

Open Access

ARTICLE

David-Dan Nguyen^1,*, Massine Fellouah^2,*, Anna-Lisa V. Nguyen³, David-Christian Kazu⁴, Isabel Baltzan⁵, Muhieddine Labban⁶, Shubha De⁷, Kevin C. Zorn⁸, Bilal Chughtai⁹, Dean S. Elterman¹, Quoc-Dien Trinh⁶, Naeem Bhojani⁸
Canadian Journal of Urology, Vol.30, No.3, pp. 11546-11550, 2023
Abstract Introduction: 5α-reductase inhibitors (5ARI) are commonly prescribed medications. There is ongoing controversy about the adverse events of these medications. The aim of this study is to characterize lawsuits in Canada involving medical complications of 5ARIs use.
Materials and methods: Legal cases were queried from CanLII. Cases were included if they involved a party taking a 5ARI who alleged an adverse event. Relevant full cases were retained, and pertinent characteristics were extracted with the help of a legal expert.
Results: Our deduplicated search yielded 67 unique legal documents from December 2013 to February 2019. Twelve of these documents met… More >

View

31

Download

40

Open Access

ARTICLE

Alon Lazarovich¹, Thenappan Chandrasekar², Alina Basnet³, Gennady Bratslavsky⁴, Hanan Goldberg⁴
Canadian Journal of Urology, Vol.30, No.3, pp. 11551-11557, 2023
Abstract Introduction: Prostate-specific antigen (PSA) testing remains a controversial issue. However, most urological guidelines recommend PSA testing in men aged 55-69 through a shared decision-making process with the patient. The impact of prior cancer diagnosis on PSA testing is not well-known. To compare PSA testing in men aged 55-69 years with and without a history of cancer (excluding prostate cancer patients).
Materials and methods: Utilizing the National Health Interview Survey (NHIS), a retrospective cross-sectional study during the year 2018 was carried out. Multivariable logistic regression analysis was implemented to demonstrate potential associations with PSA testing and assess the… More >

View

33

Download

42

Open Access

RESIDENT’S CORNER

Erin Howells¹, Lucas Wigston², Gavin Mackie¹, Ben Tran³, Louise Nott⁴
Canadian Journal of Urology, Vol.30, No.3, pp. 11558-11561, 2023
Abstract Fumarate hydratase deficient (FHdef) renal cell carcinoma (RCC) is rare, highly aggressive and is believed to arise mostly in the setting of hereditary leiomyomatosis RCC (HLRCC) syndrome with a germline mutation of fumarate hydratase (FH) gene. There is currently little evidence regarding the most effective systemic treatment for advanced FHdef RCC. We present three cases of metastatic FHdef RCC, all achieving tumor response with combination immunotherapy ipilimumab and nivolumab (Ipi/Nivo). A 50-year-old male, a 27-year-old male and a 48-year-old female. The clinical features, diagnosis and medical imaging are reviewed. More >

View

33

Download

41

Open Access

RESIDENT’S CORNER

Tariq Abdul Hamid¹, Amr Elmekresh¹, Almas Zulfiquar Parkar², Mohamad Motaz Al Masri¹, Yaser Saeedi¹
Canadian Journal of Urology, Vol.30, No.3, pp. 11562-11567, 2023
Abstract Monkeypox virus (MPV) is a rare zoonotic infection caused by an orthopoxvirus. The sudden outbreak of more than 3000 MPV infection from 50 countries has led the WHO to declare the infection as an “evolving threat of moderate public health concern”. Here, we describe a case series of two cases of the MPV with a similar onset of cutaneous lesions in the genital area but with different progression in 35 and 41-year-old males respectively. Both of our patients were reported heterosexual with a 10-day prior history of unprotected sexual activity with a sex worker. Case… More >

View

32

Download

42

Open Access

HOW I DO IT

Dean S. Elterman¹, Bruce Gao¹, Kevin C. Zorn², Naeem Bhojani², Alexis Te³, Bilal Chughtai³, Steven A. Kaplan
Canadian Journal of Urology, Vol.30, No.3, pp. 11568-11573, 2023
Abstract Benign prostatic hyperplasia (BPH) is a common and progressive disease affecting aging men which has a significant impact on quality of life. The Optilume BPH Catheter System (Optilume BPH) is a prostatic dilation system that combines balloon dilation with a localized transfer of paclitaxel to maintain long term patency. Optilume BPH can be deployed using standard rigid cystoscopy without general anesthesia in an office setting. Prospective data indicate that Optilume BPH has favorable functional and sexual patient outcomes. Readers will familiarize themselves with Optilume BPH, significant historical studies and the technique for deploying Optilume BPH. More >

View

34

Download

61

Open Access

HOW I DO IT

Andrew M. Higgins¹, Michael J. Wolf², Russell E. N. Becker¹, Khurshid R. Ghani¹
Canadian Journal of Urology, Vol.30, No.3, pp. 11574-11582, 2023
Abstract In North America, ureteroscopy has become the most popular treatment modality for upper urinary tract urinary calculi. Herein we describe our technique for the treatment of renal stones with flexible ureteroscopy and high-power holmium laser lithotripsy. We discuss preoperative planning, intraoperative strategies, and laser settings for a high-frequency dusting technique with the goal to provide optimal patient outcomes. More >

View

35

Download

50